BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10227398)

  • 1. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects.
    Goelen G; Teugels E; Bonduelle M; Neyns B; De Grève J
    J Med Genet; 1999 Apr; 36(4):304-8. PubMed ID: 10227398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
    Vaziri SA; Krumroy LM; Rostai M; Casey G
    Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
    Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
    Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H
    Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
    Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
    Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
    Ligtenberg MJ; Hogervorst FB; Willems HW; Arts PJ; Brink G; Hageman S; Bosgoed EA; Van der Looij E; Rookus MA; Devilee P; Vos EM; Wigbout G; Struycken PM; Menko FH; Rutgers EJ; Hoefsloot EH; Mariman EC; Brunner HG; Van 't Veer LJ
    Br J Cancer; 1999 Mar; 79(9-10):1475-8. PubMed ID: 10188893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
    Perkowska M; BroZek I; Wysocka B; Haraldsson K; Sandberg T; Johansson U; Sellberg G; Borg A; Limon J
    Hum Mutat; 2003 May; 21(5):553-4. PubMed ID: 12673801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
    Grzybowska E; Zientek H; Jasinska A; Rusin M; Kozlowski P; Sobczak K; Sikorska A; Kwiatkowska E; Gorniak L; Kalinowska E; Utracka-Hutka B; Wloch J; Chmielik E; Krzyzosiak WJ
    Hum Mutat; 2000 Dec; 16(6):482-90. PubMed ID: 11102977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
    Sarantaus L; Vahteristo P; Bloom E; Tamminen A; Unkila-Kallio L; Butzow R; Nevanlinna H
    Eur J Hum Genet; 2001 Jun; 9(6):424-30. PubMed ID: 11436123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
    Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
    Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk assessment for familial occurrence of breast cancer].
    Chang-Claude J; Becher H; Hamann U; Schroeder-Kurth T
    Zentralbl Gynakol; 1995; 117(8):423-34. PubMed ID: 7571905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
    Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
    Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.